These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 10872715)

  • 1. Influenza and its vaccination in HIV1-AIDS patients.
    Mathé G
    Biomed Pharmacother; 2000 May; 54(4):175-7. PubMed ID: 10872715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization with recombinant modified vaccinia Ankara (rMVA) constructs encoding the HA or NP gene protects ponies from equine influenza virus challenge.
    Breathnach CC; Clark HJ; Clark RC; Olsen CW; Townsend HG; Lunn DP
    Vaccine; 2006 Feb; 24(8):1180-90. PubMed ID: 16194586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influenza virus-stimulated generation of anti-human immunodeficiency virus (HIV) activity after influenza vaccination in HIV-infected individuals and healthy control subjects.
    Pinto LA; Blazevic V; Anderson SA; Venzon DJ; Trubey CM; Rowe T; Katz JM; Liewehr D; Dolan MJ; Shearer GM
    J Infect Dis; 2001 Apr; 183(7):1000-8. PubMed ID: 11237823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study.
    Cao H; Kaleebu P; Hom D; Flores J; Agrawal D; Jones N; Serwanga J; Okello M; Walker C; Sheppard H; El-Habib R; Klein M; Mbidde E; Mugyenyi P; Walker B; Ellner J; Mugerwa R;
    J Infect Dis; 2003 Mar; 187(6):887-95. PubMed ID: 12660934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects.
    Goepfert PA; Horton H; McElrath MJ; Gurunathan S; Ferrari G; Tomaras GD; Montefiori DC; Allen M; Chiu YL; Spearman P; Fuchs JD; Koblin BA; Blattner WA; Frey S; Keefer MC; Baden LR; Corey L;
    J Infect Dis; 2005 Oct; 192(7):1249-59. PubMed ID: 16136469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function.
    Sambhara S; Kurichh A; Miranda R; Tumpey T; Rowe T; Renshaw M; Arpino R; Tamane A; Kandil A; James O; Underdown B; Klein M; Katz J; Burt D
    Cell Immunol; 2001 Aug; 211(2):143-53. PubMed ID: 11591118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The majority of currently circulating human immunodeficiency virus type 1 clade B viruses fail to prime cytotoxic T-lymphocyte responses against an otherwise immunodominant HLA-A2-restricted epitope: implications for vaccine design.
    Altfeld M; Allen TM; Kalife ET; Frahm N; Addo MM; Mothe BR; Rathod A; Reyor LL; Harlow J; Yu XG; Perkins B; Robinson LK; Sidney J; Alter G; Lichterfeld M; Sette A; Rosenberg ES; Goulder PJ; Brander C; Walker BD
    J Virol; 2005 Apr; 79(8):5000-5. PubMed ID: 15795285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization with a DNA chimeric molecule encoding a hemagglutinin peptide and a scFv CD21-specific antibody fragment induces long-lasting IgM and CTL responses to influenza virus.
    Ivanovska N; Tchorbanov A; Prechl J; Maximova V; Voynova E; Vassilev TL
    Vaccine; 2006 Mar; 24(11):1830-7. PubMed ID: 16289708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thinking about broadly cross-reactive vaccines.
    Doherty PC; Turner SJ
    Clin Pharmacol Ther; 2009 Jun; 85(6):665-8. PubMed ID: 19404249
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein.
    Wright PF; Mestecky J; McElrath MJ; Keefer MC; Gorse GJ; Goepfert PA; Moldoveanu Z; Schwartz D; Spearman PW; El Habib R; Spring MD; Zhu Y; Smith C; Flores J; Weinhold KJ;
    J Infect Dis; 2004 Apr; 189(7):1221-31. PubMed ID: 15031791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of prophylactic AIDS vaccines: the current state of affairs.
    Hanke T
    Curr Opin Mol Ther; 2003 Feb; 5(1):25-32. PubMed ID: 12669467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on vaccine development in AIDS and cancer.
    MacDougall DS
    J Int Assoc Physicians AIDS Care; 1995 Apr; 1(3):18-24. PubMed ID: 11362485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific cytotoxic T lymphocyte responses in Chinese HIV/AIDS patients.
    Shang H; Han XX; Wang YN; Zhou LP; Zhang ZN; Jiang YJ; Zhang M; Yu X
    Chin Med J (Engl); 2004 Oct; 117(10):1570-2. PubMed ID: 15498386
    [No Abstract]   [Full Text] [Related]  

  • 14. Relationship between human immunodeficiency virus type 1 (HIV-1)-specific memory cytotoxic T lymphocytes and virus load after recent HIV-1 seroconversion.
    Connick E; Schlichtemeier RL; Purner MB; Schneider KM; Anderson DM; MaWhinney S; Campbell TB; Kuritzkes DR; Douglas JM; Judson FN; Schooley RT
    J Infect Dis; 2001 Dec; 184(11):1465-9. PubMed ID: 11709791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.
    AIDS Vaccine Evaluation Group 022 Protocol Team
    J Infect Dis; 2001 Feb; 183(4):563-70. PubMed ID: 11170981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-peplotion vaccine. A novel approach to vaccination against AIDS by transepithelial transport of viral peptides and antigens to Langerhans cells for induction of cytolytic T cells by HLA class I and CD1 molecules for long term protection.
    Becker Y
    Adv Exp Med Biol; 1996; 397():97-104. PubMed ID: 8718588
    [No Abstract]   [Full Text] [Related]  

  • 17. Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption.
    Harrer E; Bäuerle M; Ferstl B; Chaplin P; Petzold B; Mateo L; Handley A; Tzatzaris M; Vollmar J; Bergmann S; Rittmaier M; Eismann K; Müller S; Kalden JR; Spriewald B; Willbold D; Harrer T
    Antivir Ther; 2005; 10(2):285-300. PubMed ID: 15865223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunopathogenesis and immunotherapy in AIDS virus infections.
    Letvin NL; Walker BD
    Nat Med; 2003 Jul; 9(7):861-6. PubMed ID: 12835706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutant influenza A virus nucleoprotein is preferentially localized in the cytoplasm and its immunization in mice shows higher immunogenicity and cross-reactivity.
    Ohba K; Yoshida S; Zahidunnabi Dewan M; Shimura H; Sakamaki N; Takeshita F; Yamamoto N; Okuda K
    Vaccine; 2007 May; 25(21):4291-300. PubMed ID: 17403560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A recombinant live attenuated measles vaccine vector primes effective HLA-A0201-restricted cytotoxic T lymphocytes and broadly neutralizing antibodies against HIV-1 conserved epitopes.
    Lorin C; Delebecque F; Labrousse V; Da Silva L; Lemonnier F; Brahic M; Tangy F
    Vaccine; 2005 Aug; 23(36):4463-72. PubMed ID: 15993518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.